Acadia (NASDAQ: ACAD) director receives new option and RSU awards

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS director Jonathan Poole received new equity awards as part of his compensation. On March 3, 2026, he was granted 7,482 director stock options with a $22.50 exercise price that vest in equal annual installments over three years, and 3,565 additional options at the same exercise price that vest quarterly over one year, with the final tranche vesting on the earlier of one year after grant or the next annual stockholder meeting. He was also granted 4,218 restricted stock units that vest in equal annual installments over three years and 2,010 restricted stock units that vest in full on the earlier of one year after grant or the next annual stockholder meeting. Each restricted stock unit represents the right to receive one share of common stock upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poole Jonathan

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Options (Right to Buy)	$22.5	03/03/2026		A		7,482		(1)	03/02/2036	Common Stock	7,482	$0	7,482	D
Director Stock Options (Right to Buy)	$22.5	03/03/2026		A		3,565		(2)	03/02/2036	Common Stock	3,565	$0	3,565	D
Restricted Stock Units	(3)	03/03/2026		A		4,218		(4)	(4)	Common Stock	4,218	$0	4,218	D
Restricted Stock Units	(3)	03/03/2026		A		2,010		(5)	(5)	Common Stock	2,010	$0	2,010	D

Explanation of Responses:

1. The shares subject to the stock option will vest in equal annual installments over three years following the date of grant such that the stock option will be fully vested on the third anniversary of the date of grant.

2. The shares subject to the stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

3. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

4. The restricted stock units will vest in equal annual installments over three years following the date of grant such that the restricted stock units will be fully vested on the third anniversary of the date of grant.

5. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did ACAD (ACADIA PHARMACEUTICALS) report for Jonathan Poole?

ACADIA PHARMACEUTICALS reported that director Jonathan Poole received grants of stock options and restricted stock units on March 3, 2026. These equity awards are part of his director compensation and vest over one- and three-year schedules tied to service and the next annual stockholder meeting.

How many stock options were granted to ACAD director Jonathan Poole and at what exercise price?

Jonathan Poole was granted 7,482 director stock options and an additional 3,565 options, each with a $22.50 per share exercise price. The larger grant vests annually over three years, while the smaller grant vests quarterly over one year or until the next annual stockholder meeting.

What restricted stock unit (RSU) awards did Jonathan Poole receive from ACADIA PHARMACEUTICALS?

Jonathan Poole received 4,218 restricted stock units and 2,010 restricted stock units. The 4,218 units vest in equal annual installments over three years, while the 2,010 units vest in full on the earlier of one year after grant or the next annual meeting of stockholders.

How do the vesting schedules work for Jonathan Poole’s ACAD stock option grants?

One stock option grant of 7,482 shares vests in equal annual installments over three years. The second grant of 3,565 shares vests quarterly over one year, with the final tranche vesting on the earlier of one year after grant or the next annual stockholder meeting.

What does each restricted stock unit granted to ACAD director Jonathan Poole represent?

Each restricted stock unit granted to Jonathan Poole represents a contingent right to receive one share of ACADIA PHARMACEUTICALS common stock. Shares are delivered only as the units vest under the specified three-year schedule or upon the earlier of one year or the next annual stockholder meeting.

When do Jonathan Poole’s new ACAD stock options expire?

Jonathan Poole’s director stock options granted on March 3, 2026 carry an expiration date of March 2, 2036. They remain exercisable until that date, subject to their vesting conditions and any applicable service or plan requirements set by ACADIA PHARMACEUTICALS.